This study describes a 12 ± 24 month follow-up on 119 ED patients in an attempt to understand satisfaction with and dropout from ICI use. Results indicate 40% attrition, attributed primarily to a lack of ef®cacy of ICI, but also to spontaneous return of erectile function and to negative reactions surrounding the injection procedure. Multivariate analyses indicated that ICI dropouts were more likely to have co-existing premature ejaculation, low responses during psychophysiological screening, a lack of spontaneous erections prior to ICI, and an etiology that included an organogenic component. These same factors, along with low satisfaction with their sex life, were related to attrition due speci®cally to a lack of drug ef®cacy. In contrast, attrition due to recovery of spontaneous erections was associated with high sexual satisfaction. Among ongoing users, dissatisfaction was associated with higher age, shorter erections during ICI use, and low satisfaction with sex life. These ®ndings identify a number of factors related to attrition and satisfaction, emphasizing the importance of specifying the cause for ICI attrition and, demonstrating that a substantial portion of patients who dropout do so for positive reasons.
Introduction
Intracavernosal self-injection therapy (ICI) with vasoactive compounds is counted among the standard therapeutic options available to men with erectile problems. With ongoing development over the past 15 y, this treatment has come to provide a safe and effective means for self-management of this dysfunction. 1 ± 3 In fact, newer compounds such as prostaglandin E1 boast response rates of well over 50% with lowered risks of unwanted side effects such as priapism. 4 ± 7 ICI may improve sexual satisfaction in other ways as well. It may facilitate the return of spontaneous erections in patients with signi®cant psychogenic etiology by breaking the vicious cycle of failure, it may alleviate psychological distress associated with feelings of low selfef®cacy, and ultimately it may improve aspects of the dyadic relationship. 8, 9 Despite the bene®cial effects of ICI, the attrition rate among ED men is high, in the vicinity of 40 ± 60% or higher, 10 ± 13 and not surprisingly, the acceptance of this treatment as a long term therapy has been questioned. 12 Furthermore, with the recent introduction of oral medication such as sildena®l 14 for the management of erectile problems, the population of ICI users will undoubtedly become smaller and more select. Therefore, an important aspect of treatment with intracavernosal vasoactive agents lies not just in its effectiveness in stimulating erections, but also in understanding factors responsible for patient acceptance and attrition. 12, 15 In this present study we describe a 12 ± 24 month follow-up of the experiences of a group of ED men opting for ICI, and we compare responses across ongoing and attritant users. We were particularly interested in understanding factors related to satisfaction with ICI, why some men terminated ICI, and to what extent the return of spontaneous erections might have played a role in its discontinuation. We examined a number of demographic and diagnostic variables, as well as the quality of the preparatoryatraining steps for patient and partner, in an attempt to predict long-term ICI acceptance and to verify purported relationships reported previously between such factors (age) and long-term use. 11, 15 Finally, we were interested in whether ED patients with concurrent premature ejaculation (PE) deviated in their response patterns from men with just ED. Previous research has indicated that men with concurrent ED and PE often respond differently than men with just ED, both physically and subjectively, to sexual problems and to the therapies directed toward them. 16, 17 Materials and methods
Subjects
Subjects for this study were drawn from the total population of patients choosing intracavernosal selfinjection therapy (ICI) for management of their erectile problem during 1994 ± 95 following consultationadiagnosis in the urology outpatient clinic of an academic hospital. Vasoactive agents included papaverine, androskat (papaverine phentolamine), or alprostadil (prostaglandin E1). Effective doses for patients were determined by at least one, and often two or more, visits to the clinic or lab where administration of the vasoactive compound was conducted by a urologist or under a urologist's guidance. Patients having inadequate erectile response at home were instructed to consult the urology clinic (through visitation or phone) to discuss the possibility of increasing the dose.
Patients were identi®ed through an on-line crosslisting in a hospital data bank using two parameters: a diagnosis of erectile dysfunction (ED), and the prescription for self-injection therapy. The majority of this population had undergone psychophysiological investigation as part of their diagnosis of sexual dysfunction. Of the 168 patients identi®ed as ICI users, 36 could not participate because they had moved, were physically disabled or died, or were unable to understand the questions due to a language barrier. Of the remaining 132 patients, 11 chose not to participate. As two questionnaires lacked suf®cient information to warrant inclusion in the analyses, results are based on the ®nal sample of 119 patients (90% participation rate for patients located and able).
Response measures
Data from two sources were used in this analysis. Prior to starting self-injection therapy, most patients (n 108; 91%) had participated in a screening session in which their sexual response was assessed to visual sexual stimulation (VSS), VSS combined with penile vibrotactile stimulation (VSS VIB), and for those who showed no or a low response to these stimuli, intracavernosal injection of a vasoactive agent administered in conjunction with VSS VIB. 18 Under each of the three stimulus conditions described above, data on the patient's erectile response (determined with an erectiometer 19 ), overall subjective arousal (1 not at all, 6 very high) and estimated % of full erection (100 mm analog scale) were available for analysis. Speci®cally, in this screening, men who selfreported fairly strong erections (60% of higher) during VSS VIB were often not tested further with ICI VSS VIB. For the purpose of this study, these men, along with those tested under ICI VSS VIB reporting erections of 80% or higher, formed a category of moderate-strong responders. This group was then contrasted with lowaabsent responders with respect to attrition.
In addition to information from psychophysiological screening, several other factors that were known prior to attrition were available for analysis. These included the speci®c vasoactive substance, the patient's age, the most likely origin of the erectile dysfunction (primarily psychogenic, primarily organogenic, or mixed psychoaorganogenic), the length of the ED, and whether or not ED was accompanied by premature ejaculation.
At the 12 ± 24 month follow-up, participants completed a self-injection therapy (ICI) questionnaire designed speci®cally for this study. In brief, this four-part questionnaire consisted of 57 items, but depending on the patient's current status with respect to self-injection therapy, a maximum of 36 questions required answering. The ®rst part (13 items) solicited information about the patient's current relationship status, sexual functioning, and frequencies of sexual activities. The second (5 items) asked about sexual function and ICI preparationatraining prior to the beginning of the therapy. The ®nal two parts essentially duplicated one another, with one version (18 items) intended for patients who had discontinued ICI, the other (16 items) for patients who reported ongoing use of ICI. These items pertained to how ICI was used, its effectiveness, the patient's general satisfaction, and partner's response to ICI (through the patient). All items followed a checklist format, with each response possibility accompanied by a verbal description. For a number of items, the option of completing an open-ended response was provided if the patient felt the response categories did not apply to his situation. When possible, these answers were recoded to one of the existing response categories.
Procedure
Participants were ®rst contacted by phone by one of the investigators (AKS) and asked whether they were interested in and willing to participate in the follow-up survey. Those who provided consent were mailed the questionnaire along with a preaddressed, stamped return envelope. If the questionnaire was not returned within two weeks, the Intracavernosal self-injection therapy in men with ED DL Rowland et al patient was contacted again by phone and queried with no pressure as to whether he still wanted to complete the questionnaire and if so whether he had problems understanding any of the items. At this time, participants were given the further options of completing the questionnaire either over the phone or during their next scheduled visit to the clinic or lab. Completed questionnaires were scrutinized for incomplete or erroneous responses (for example, when it was clear that the respondent had misinterpreted the item), and when feasible, respondents were contacted again for clari®cation of their response.
Data reduction and analysis
Data for analysis were entered by a medical research associate and checked for errors by another member of the research team. Analyses were carried out using the DBase and SPSS software systems. Individual psychophysiological variables and questionnaire items were ®rst related to the dichotomous outcome variable, whether or not ICI had been discontinued, through simple bivariate analyses (for example, simple correlation, chi square, t-tests).
Variables suggesting relationships (P`0.10) to the outcome variable or having a priori relevance (for example, satisfaction with erections during ICI) were then considered for inclusion in a multivariate logistic regression analysis. Prior to inclusion, predictor variables were checked for collinearity and redundant items (r b 0.20) were omitted from the regression analysis. When analyses included items pertinent to relationship issues, patients without partners (n 13) were excluded from the analysis. We separated variables in the analyses into two groups. The ®rst consisted of factors that were known prior to the onset of ICI (for example, results of psychophysiological screen, diagnostic variables, and so on) or that retrospectively referred to conditions prior to ICI onset. We refer to this set of factors as prior variables, because temporally they were positioned before ICI use and therefore could be viewed as predictors of attrition. The second set of variables consisted of factorsaconditions occurring either simultaneously with ICI use or at the time of their response to the survey (thus, for some patients descriptions of current sexual functioning referred to conditions after ICI termination). We refer to these factors as contemporaneous covariates, because they described conditions during or after ICI use.
Further analyses were carried out to explore hypothetical relationships among predictor variables and satisfaction outcomes with ICI in ongoing users, and to specify the role of preparationatraining in ICI use with various negative outcomes, including attrition and dissatisfaction with ICI.
Results
The men in this study, whose average age was 58 y (SE 0.89 y), indicated erection problems for an average duration of 41 months (SE 3.3 months) prior to ICI therapy. A subset of men (15%) reported co-existing premature ejaculation. On average, respondents (had) used ICI 3.5 times per month but rated their current sex lives as less than satisfactory (3.3 on a 7-pt scale, where 1 very bad, 7 very good). Regarding their original complaint, 35% of respondents indicated the situation had improved, 42% indicated no change, and 23% indicated a worsening.
Men who terminated ICI
Forty percent of the sample (n 48) discontinued ICI after an average of 9 months of use (Table 1) . Although the most frequent reason for discontinuation was lack of ef®cacy (n 20; 43%), 21% (n 10) indicated that spontaneous erections had returned and therefore the need for ICI was eliminated. An additional 21% (n 10) dropped out because of procedural aspects surrounding the injection Ð side effects or convenienceaperceptual factors (for example, dif®culty of injection, needle aversion, or negative partner response). Eight dropouts (17%) elected for another form of therapy after terminating ICI, with three choosing a prosthetic device, four a vacuum device, and one a combination of vacuum device and elastic constrictor. Of these, three indicated satisfaction with the new alternative (2 prosthetic, 1 vacuum).
Comparison of ICI terminators and continuers
Men who discontinued ICI did not differ from continuing ICI users on a number of demographic [2] 0.995; P b 0.40). To control for experimentwise error and possible correlations among covariates of ICI attrition, two multivariate logistic regressions were carried out on the signi®cant variables using attrition as the outcome variable. In the ®rst, non-redundant covariates (r`0.20) known prior to the outcome (attrition) were entered; these included the vasocactive agent, age, patient's estimated penile response during psychophysiological screening (this variable correlated with actual erectile response [r 0.37] which was therefore omitted from the analysis), assessed etiology (primarily organogenic, primarily psychogenic, both, or undetermined), and concurrent PE. In the second analysis, covariates contemporaneous with current attrition status were entered to identify factors associated with ongoing ICI use or attrition.
Results indicated three independent factors prior to ICI use that were associated with increased probability of attrition (Table 2) : the reported absence of spontaneous erections prior to ICI; concurrent premature ejaculation; and lower erectile response during psychophysiological screening. The combined effect of these three factors generated an overall odds ratio of 6.34, that is, a man showing all three characteristics was 6.3 times more likely to drop out than a man having none of the characteristics. Construction of an ordinally-scaled attrition risk index based on the three signi®cant predictors (0 no risk to 4 maximum of all three risks present) indicated that an increasing number of risk factors greatly increased the probability of attrition. Speci®cally, this analysis (data not shown) indicated that the presence of any one of the factors above (no matter what it was) greatly increased the probability of attrition (10 times), but that additional factors beyond the ®rst only moderately (second risk factors; 4 times) or weakly (third risk factor; 1.3 times) further increased this probability.
The second analysis examined contemporaneous covariates of attrition, that is, factors concomitant with ICI use. Attrition was associated with a lower level of satisfaction with one's current sexual life (`satisfaction' correlated signi®cantly with reported coital frequency, r 0.39; P`0.001), diminished frequency of masturbation during ICI use, and proportionately higher rates of ICI use (ratio of frequency of ICI use to frequency of overall sexual activity with partner) during the period of selfinjection therapy.
Factors related to speci®c reasons for attrition
The majority of patients terminating ICI use did so for negative reasons, namely lack of drug ef®cacy or undesirable conditions surrounding the injection procedure. However, over 20% stopped using ICI for a positive reason, namely the return of spontaneous erectile function. Therefore, predictor variables for these different subgroups of ICI terminators were likely to be different, with the factors identi®ed above weighted heavily toward`negative' attrition. As a result, data were re-analyzed separating positive attrition patients from negative attrition patients. Logistic regression analyses were used ®rst to compare continuing users against`positive' dropouts, and then to compare continuing users against`negative' dropouts.
Regarding factors prior to ICI, four increased the odds of attrition due to lack of drug ef®cacy: an etiology that included an organogenic component (P 0.024), low response during psychophysiological screening (P 0.018), a lack of spontaneous erections prior to ICI onset (P 0.035), and marginally, concurrent PE (P 0.060). The overall odds ratio for the combined factors indicated that a patient showing all three conditions was 16.8 times more likely to terminate ICI use than a patient showing none. In contrast, no prior factors predicted attrition due to side effects or convenienceaperceptual factors (negative responses by the patient or a This ratio represents the probability of the one outcome (attrition) to the other (continuation).
Intracavernosal self-injection therapy in men with ED DL Rowland et al partner surrounding the injection procedure). One factor, an etiology that included an organogenic component, predicted attrition resulting from the return of spontaneous erections (P 0.039; odds ratio 2.7). The only contemporaneous factor associated with attrition for any particular reason was sexual satisfaction. Speci®cally, discontinuation of ICI due to either side effects (P 0.038) or lack of ef®cacy (P 0.009) was associated with lower current sexual satisfaction, whereas discontinuation due to recovery of spontaneous erections was associated with higher sexual satisfaction (P 0.029). When discontinuation due to any negative reason (lack of ef®cacy, side effects, partner aversion, dif®culty with injection) was viewed as the outcome, two factors beyond low sexual satisfaction (P 0.001) were associated with attrition: a lower frequency of masturbation (P 0.015) and a higher rate of ICI usage with the partner (P 0.055). A third factor, absence of spontaneous erections during the period of ICI usage, was marginally associated with increased attrition (P 0.080).
Factors related to ongoing satis®ed (or dissatis®ed) use of ICI
Ongoing users were asked about their satisfaction with ICI, with response categories including`satis®ed,'`neither satis®ed or unsatis®ed,' and`unsatis®ed' (see Table 1 ). Both prior and current factors were explored in relation to these outcomes in this group.
The patient's age was the only factor known prior to ICI onset that predicted ICI dissatisfaction among current users (P 0.044); older patients were more likely to express dissatisfaction with ICI. Two factors concurrent with ICI use were associated with dissatisfaction: a lower level of satisfaction with sexual functioning (P 0.011; this variable correlated with lower frequencies of sex with their partners), and shorter duration of erections during ICI (P 0.023).
The role of preparationatraining in ICI use by the physician
Patients were asked whether they had watched the instructional video about self-injection and furthermore, the extent to which they felt they had received adequate training in the self-injection procedure. Neither item was related to attrition, or to any speci®c reason given for attrition. However, the less adequate the training was judged, the higher the reported number of different adverse side effects (P 0.025). In addition, those who found the training inadequate reported a higher incidence of priapism (erections lasting from 4 ± 10 h requiring treatment by the urologist) (P 0.048) and bleedingahematomas (P`0.001). Current ICI users reported greater satisfaction with ICI if they had watched the instructional video with their partner, an event that was more likely to occur when patients also reported a good dyadic relationship with her.
Discussion
With the advent of transurethral and oral pharmacotherapies, the use of ICI for the management of Intracavernosal self-injection therapy in men with ED DL Rowland et al erectile problems will undoubtedly diminish, at least temporarily. These alternative approaches have their own drawbacks (for example, burning pain with transurethral treatment, side effects such as headaches and visual disturbances with oral therapy, and even possible mortality), and their ef®cacy and side effects have yet to be assessed over the long-term. Accordingly ICI will remain an option for a subset, albeit more select than before, of men with ED andaor PE. This present study helps establish a pro®le of the ED patient most likely to discontinue ICI use, and of the ongoing user most likely to report dissatisfaction with ICI. Equally important, this study emphasizes the contrasting positive and negative reasons for attrition, reveals speci®c factors related to these very different reasons for attrition (Table 3) , and suggests that the general response to ICI ef®cacy and procedures is more important to understanding attrition than speci®c factors related to any particular vasoactive substance.
We found that overall attrition was higher in ED men with an organogenic component to their ED diagnosis or with concurrent premature ejaculation. In addition, men showing lower responses during psychophysiological screening showed higher probability of attrition. The presence of any one of the above factors imparted the greatest probability of attrition, with each additional factor adding proportionately less. Such factors, combined with higher rates of ICI use prior to attrition and the absence of spontaneous erections prior to ICI use, presumably signal low erectile potential and therefore lower effectiveness of the vasoactive agent. Indeed, factors associated with attrition in general were the same ones most strongly associated with attrition due speci®cally to lack of ICI ef®cacy, the most prevalent reason cited for discontinuation in this study. Not surprisingly, ICI termination due to lack of ef®cacy was strongly associated with low levels of sexual satisfaction among patients.
Side effects accounted for less than 10% of attrition, a percentage comparable with other studies of this type.
10Y11 When attrition from side effects was combined with attrition from other negative (non-pharmacological) aspects surrounding ICI injection (convenienceaperceptual factors), the rate was 20%. However, as reported in previous research, 10 a higher level of side effects or`inconvenience' did not appear to strongly distinguish dropouts from ongoing users. Among those who indicated side effects or inconvenience as their reason for dropping out, only one side effect, curvature of the penis, was found to actually occur more frequently (P 0.026, post hoc analysis not reported in Results). Therefore, it seems that dropouts do not necessarily have more negative experiences with ICI, but rather that they are less tolerant of those negative experiences. This lower tolerance may be due to lower motivation for sex andaor lower satisfaction derived from ICI therapy. We found, for example, that low levels of masturbation were associated with ICI termination. Accordingly, high libido and greater openness to diverse forms of sexualasensual experiences may be the kinds of factors that increase the patient's tolerance of negative effects from ICI use. They may also help to increase overall sexual satisfaction during ICI treatment, typically low in men undergoing treatment for ED. 20 The patient's (and partner's) perceptions of the injection procedure undoubtedly play a role in acceptance of ICI. Although no direct relationships between such`convenienceaperceptual' factors and attrition were identi®ed in this study, an indirect link between inadequate trainingapreparation for self-injection (from both a procedural and psychological standpoint for patient and partner) and attrition is suggested, since patients reporting insuf®cient training also reported a higher incidence of negative side effects. Such ®ndings stress the importance of adequate training and preparation in reducing unwanted effects from ICI. 21 Current satis®ed ICI users and dissatis®ed ICI exusers represent opposite endpoints along the continuum of attrition risk. The former group is at low risk for attrition due to negative factors, whereas the latter has exhibited maximal risk, having already chosen to drop out. A group intermediate between these two extremes is that of dissatis®ed current users (12% of the current sample). Without counseling, these men would presumably form the next transition group from ICI users to dissatis®ed exusers. 21, 22 Our study identi®ed two factors related to dissatisfaction among current ICI users. These factors, increasing age (reported as an issue in ICI dissatisfaction in previous studies 11, 15 ) and shorter duration of ICI erections, are both likely to nudge the patient toward attrition. Yet interestingly, there was only minor overlap between variables associated with dissatis®ed users and those with dissatis®ed ex-users, suggesting that the former status may not simply be a precursor to the latter. We believe that further exploration through prospective analysis of dissatis®ed users, and of strategies that might address the concerns of this group, is warranted.
As demonstrated in this and other studies, 12, 13, 23, 24 some attrition (21%) occurred for a positive reason, namely elimination of the erectile dysfunction through recovery of spontaneous erections. These ex-users reported a high degree of satisfaction. This outcome is not surprising in men with psychogenic ED who regain their potency. 25 However, the ®nding that men with partial organogenic ED were as likely to report terminating ICI therapy due to recovery of spontaneous erections is interesting. Although misdiagnosis and placebo effects may account for some of this recovery, ICI itself may impart therapeutic effects that promote at least partial recovery of arterial function, an idea Intracavernosal self-injection therapy in men with ED DL Rowland et al that has received moderate support from several studies.
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Conclusions A large percent of dropouts reported lack of ef®cacy, discomfort, and side effects surrounding ICI use as their reasons, although the actual number of adverse effects in this group was barely discernible from ongoing users. Therefore, dropouts may be less tolerant of the negative effects that do occur. This group also showed the weakest penile response on a number of measures prior to their use of ICI, and they more frequently reported concomitant premature ejaculation. Ongoing ICI users reported highest satisfaction if they were younger and if they felt the injections produced erections of adequate duration. Adequate training in the injection procedure to minimize adverse effects and produce maximal response, inclusion of the partner in the deceision to use ICI, and openness to forms of sexual expression other than intercourse may be important to reducing attrition among users. Twenty-one percent of dropouts reported the return of erectile capacity, and as expected these men indicated a high level of satisfaction with their current sex lives.
